FMP

FMP

Enter

MDGL - Madrigal Pharmaceuti...

Terminal Value of Madrigal Pharmaceuticals, Inc.(MDGL), Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the developme

photo-url-https://financialmodelingprep.com/image-stock/MDGL.png

Madrigal Pharmaceuticals, Inc.

MDGL

NASDAQ

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

276.01 USD

-0.71 (-0.257%)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep